Advances in SLE Treatment: The IRAK1/4 Inhibitor R835 as a Promising Therapeutic Agent

3 June 2024
Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder that manifests through the breakdown of immune tolerance, leading to immune cell hyperactivity, proinflammatory cytokine generation, and end-organ damage due to immune complex accumulation. Toll-like receptors (TLRs), crucial for innate immune reactions to pathogens and danger signals, are implicated in SLE's development by recognizing self-proteins. Interleukin receptor-associated kinases (IRAK) 1 and 4 initiate MyD88-dependent signaling pathways from TLRs and Interleukin-1 Receptors (IL-1R), making them promising targets for SLE therapy. A phase 1 study has shown that R835, a potent and selective IRAK1/4 inhibitor, significantly reduced LPS-induced serum cytokines in healthy volunteers.

The objective of the study was to explore the therapeutic potential of IRAK1/4 inhibition in SLE by assessing the impact of R835 on TLR7 signaling and its efficacy in a mouse model exhibiting lupus-like symptoms.

The methodology involved stimulating human primary dendritic cells and whole blood with gardiquimod, a TLR7 agonist, to measure R835's effect on Interferon-alpha (IFN-α) production. The compound was also tested for its effectiveness on survival and disease progression in lupus-prone NZB/W F1 mice, either at an early stage or with active disease.

The results showed that R835 effectively suppressed TLR7-induced cytokine production in human cells and reduced serum IFN-α levels in mice in a dose-dependent manner following TLR7 agonist administration. In lupus-prone mice, R835 treatment reversed the progression of the disease and the establishment of a pro-inflammatory environment, evidenced by decreased proteinuria, blood urea nitrogen, autoantibodies, and improved renal pathology.

R835 is the first dual IRAK1/4 inhibitor to enter clinical trials and presents a promising therapeutic approach for autoimmune and rheumatic diseases, including SLE. The study's authors are affiliated with Rigel Pharmaceuticals, indicating a potential conflict of interest.

How to Use Synapse Database to Search and Analyze Translational Medicine Data?

The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

图片包含 应用程序

描述已自动生成

Click on the image below to go directly to the Translational Medicine search interface.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成